Publication date: Feb 07, 2025

The use of continuous glucose monitoring (CGM) in the hospital setting is growing, with more patients using these devices at home, especially during the COVID-19 pandemic. Frail and critically ill patients with COVID-19 and previously normal glucose tolerance are also associated with variability in their glucose levels during their intensive care unit (ICU) stay. However, very limited evidence supports the use of CGM in ICU settings, especially among frail patients with COVID-19. We aimed to investigate the effectiveness of CGM on ICU-related outcomes among frail and critically ill patients with confirmed COVID-19. This was an exploratory, prospective, open-label, parallel, single-center, randomized controlled trial. A total of 124 patients was finally analyzed. The primary outcome was 28-day, in-ICU mortality. The secondary outcome included the length of ICU stay as well as the occurrence of hypoglycemia and severe hypoglycemia events. The mean age was 78. 3 (SD 11. 5) years. The mean fasting glucose level and hemoglobin A level at baseline were 8. 12 (SD 1. 54) mmol/L and 7. 2% (SD 0. 8%), respectively. The percentage of participants with diabetes was 30. 6% (38/124). The corresponding hazard ratio of the primary outcome in the intermittently scanned CGM (isCGM) group when compared with the point-of-care testing (POCT) group was 0. 18 (95% CI 0. 04-0. 79). The average length of ICU stay was 10. 0 (SD 7. 57) days in the isCGM group and 14. 0 (SD 6. 86) days in the POCT group (P=. 02). At the end of study period, the mean value of fasting glucose in the isCGM group and the POCT group was 6. 07 (SD 0. 63) mmol/L and 7. 76 (SD 0. 62) mmol/L, respectively (P=. 01). A total of 207 hypoglycemia events (

Open Access PDF

Semantics

Original Article